AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
We haven't written up this one. Hindustan Times - World News has the full story — the link below goes straight to it.